PIAS3 expression in human gastric carcinoma and its adjacent non-tumor tissues - 25/05/11
, Ming-guo Yan a, b, Dao-hua Yang a, Wei-wei Sun a, Ji-xiang Zhang b
Corresponding author. Tel.: +86 21 67720053.Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 6 |
| Iconografia | 2 |
| Video | 0 |
| Altro | 0 |
Summary |
Objective |
PIAS3 is the endogenous inhibitor of STAT3, which has been implicated in the pathogenesis of many cancers. However, the effect of PIAS3 on human tumors remains elusive. The aim of this article is to investigate the expression of PIAS3 in gastric carcinoma and its adjacent non-tumor tissues.
Methods |
Samples were taken from 30 patients with gastric cancer, which included tumor or non-tumor tissues in the excised sections. The expression of PIAS3 protein was detected by immunocytochemistry, and that of mRNA by in situ hybridization. The results were semi-quantitative analyzed by using cell count and color depth to stage.
Results |
The expression levels of PIAS3 protein and mRNA were significantly lower in gastric cancerous tissues than in its adjacent non-tumor tissues, and had a close relation with tumor size and differentiation, but not with age, gender and lymphatic metastasis in gastric carcinoma. The more large in size and poorly in differentiation, the more low PIAS3 expression was.
Conclusion |
Loss of PIAS3 expression may be an important characteristic of gastric cancer and suggest vicious degree of the tumor.
Il testo completo di questo articolo è disponibile in PDF.Keywords : PIAS3, Gastric cancer, Non-tumor tissues, Immunocytochemistry, In situ hybridization
Mappa
Vol 35 - N° 5
P. 393-398 - Maggio 2011 Ritorno al numero
Articolo precedente
- Lack of association of GSTT1 and GSTP1 genes methylation and their expression profiles with risk of NAFLD in a sample of Iranian patients
- Dor Mohammad Kordi-Tamandani, Mohammad Hashemi, Elnaz Birjandian, Ali Bahari, Jafar Valizadeh, Adam Torkamanzehi
- Cost of pretherapeutic staging of patients with colorectal cancer metastases in a French population
- Catherine Lejeune, Pierre Logé, Patrick Arveux, Michel Velten, Damien Jolly, Marie-Christine Woronoff-Lemsi, Francis Guillemin
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?